Geoffrey Alan Block MD

Nephrology•Lone Tree, CO

Physician

Join to View Full Profile

9777 S Yosemite StSte 110Lone Tree, CO 80124
Phone+1 720-696-0852
Fax+1 720-696-0892

Education & Training

University of MichiganFellowship, Nephrology, 1995 - 1997
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1991 - 1995
University of Cincinnati College of MedicineClass of 1991

Certifications & Licensure

CO State Medical License 1997 - 2027
TX State Medical License 2022 - 2023
WY State Medical License 2020 - 2023
MI State Medical License 1995 - 1999
OH State Medical License 1992 - 1996
American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
Fellow (ASNF) American Society of Nephrology

Clinical Trials

Treatment Protocol of Replagal for Patients With Fabry Disease
No longer available
Double Blind Randomized Placebo Controlled Trial of FOSTRAP Chewing Gum in Patients With CKD and Hyperphosphatemia Start of enrollment: 2010 Jan 01
Completed
Phase 1
Salivary Phosphorus and Level of Kidney Function Start of enrollment: 2011 Mar 01
Completed
PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum Start of enrollment: 2011 Jul 01
Completed
Not Applicable
Circadian Rhythm Modulation by Dietary Phosphorus in Chronic Kidney Disease Start of enrollment: 2011 Apr 01
Completed
Not Applicable
Phosphate Binding of Chitosan Chewing Gum in Patients With Chronic Kidney Disease (CKD) Start of enrollment: 2011 Mar 01
Completed
Early Phase 1
Dose Finding Study to Treat High Phosphate Levels in the Blood. Start of enrollment: 2014 Mar 01
Completed
Phase 2
Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D Start of enrollment: 2015 Mar 01
Completed
Phase 3
The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR) Start of enrollment: 2015 Oct 01
Completed
Phase 3
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL Start of enrollment: 2017 Mar 02
COMPLETED
PHASE2, PHASE3
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX Start of enrollment: 2017 Dec 26
COMPLETED
PHASE2
Join now to see all

Publications & Presentations

PubMed

1 citations
Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD.
Bernard Chan, Amanda Varghese, Sunil V Badve, Roberto Pecoits-Filho, Murilo Guedes
Kidney International Reports. 2025-04-01
4 citations
Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.
Stuart M Sprague, Daniel E Weiner, David P Tietjen, Pablo E Pergola, Steven Fishbane
Kidney360. 2024-05-01
14 citations
Use of Wastewater Metrics to Track COVID-19 in the US.
Meri R J Varkila, Maria E Montez-Rath, Joshua A Salomon, Xue Yu, Geoffrey A Block
JAMA Network Open. 2023-07-03

Press Mentions

Vexev and U.S. Renal Care Complete Enrollment in Groundbreaking Trial Evaluating Use of Robotic Ultrasound Scanning for AV Fistula Mapping in Dialysis ClinicsJuly 29th, 2025
Phosphates May Make You Feel LazyFebruary 6th, 2019
Experimental Drug Could Help Treat Genetic Disease Affecting the KidneysAugust 10th, 2018
Join now to see all

Professional Memberships

American Society of Nephrology - ASN
Fellow